AquaBounty Technologies, Inc. (NASDAQ:AQB) Short Interest Down 26.6% in February

AquaBounty Technologies, Inc. (NASDAQ:AQB) was the target of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 150,900 shares, a drop of 26.6% from the January 31st total of 205,500 shares. Currently, 4.0% of the company’s shares are short sold. Based on an average daily trading volume, of 480,600 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Trading of AquaBounty Technologies

A hedge fund recently raised its stake in AquaBounty Technologies stock. Epiq Partners LLC boosted its position in AquaBounty Technologies, Inc. (NASDAQ:AQB) by 423.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,000 shares of the company’s stock after purchasing an additional 72,000 shares during the quarter. Epiq Partners LLC owned approximately 2.30% of AquaBounty Technologies worth $56,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.92% of the company’s stock.

AquaBounty Technologies Trading Up 1.7 %

Shares of AquaBounty Technologies stock traded up $0.01 during midday trading on Tuesday, reaching $0.67. 9,799 shares of the company’s stock traded hands, compared to its average volume of 140,525. The stock has a 50 day moving average of $0.75 and a 200-day moving average of $0.93. AquaBounty Technologies has a 12 month low of $0.47 and a 12 month high of $2.59. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.98 and a current ratio of 3.02. The company has a market cap of $2.60 million, a PE ratio of -0.04 and a beta of 1.18.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc, a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts.